Cui Cheng, Qu Yuchen, Sia Jie En Valerie, Zhu Zhu, Wang Yang, Ling Jing, Li Haiyan, Jiang Yan, Pan Jie, Liu Dongyang
Department of Cardiology, Peking University Third Hospital, Beijing, China.
Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.
Clin Pharmacokinet. 2022 Dec;61(12):1789-1800. doi: 10.1007/s40262-022-01184-5. Epub 2022 Nov 15.
P-glycoprotein (P-gp) is one of the most intensely studied transporters owing to its broad tissue distribution and substrate specificity. Existing research suggests that the risk of systemic exposure to dabigatran etexilate (DABE) and digoxin, two P-gp probe substrates in vivo, has significantly increased in elderly patients. We applied a model-based quantitative pharmacological approach to assess aging-related P-gp changes in the Chinese old-elderly population.
Population pharmacokinetic (PopPK) modeling was first performed using clinical pharmacokinetic data to explore the effect of age on the pharmacokinetic characteristics of dabigatran (DAB, the active principle of DABE) and digoxin in elderly Chinese patients. Corresponding physiologically based pharmacokinetic (PBPK) models were established to further explain the elevated systemic exposure to these two drugs. Eventually, standard dosing regimens of DABE and digoxin were assessed in Chinese old-elderly patients with chronic heart failure (CHF) with different stages of renal impairment.
PopPK analysis suggested that age as a covariate had an additional effect on the apparent clearance of these two drugs after correcting for creatinine clearance. PBPK simulation results suggested that disease-specific pathophysiological changes could explain DAB exposure in the young elderly. In the elderly population, 17.1% of elevated DAB exposure remained unexplained, and 25.5% of the reduced P-gp function associated with aging was ultimately obtained using sensitivity analysis. This value was further validated using digoxin data obtained by PBPK modeling. The simulation results suggest that CHF patients with advanced age and moderate-to-severe renal impairment require heightened vigilance for elevated exposure risk during the use of DABE and digoxin.
Aging might be a significant risk factor for elevated systemic exposure to DAB and digoxin by reducing P-gp-mediated efflux in the Chinese old elderly population.
P-糖蛋白(P-gp)因其广泛的组织分布和底物特异性,是研究最为深入的转运蛋白之一。现有研究表明,体内两种P-gp探针底物达比加群酯(DABE)和地高辛的全身暴露风险在老年患者中显著增加。我们应用基于模型的定量药理学方法评估中国高龄老年人群中与衰老相关的P-gp变化。
首先使用临床药代动力学数据进行群体药代动力学(PopPK)建模,以探讨年龄对中国老年患者中达比加群(DAB,DABE的活性成分)和地高辛药代动力学特征的影响。建立相应的生理药代动力学(PBPK)模型以进一步解释这两种药物全身暴露增加的原因。最终,评估了不同肾功能损害阶段的中国高龄老年慢性心力衰竭(CHF)患者中DABE和地高辛的标准给药方案。
PopPK分析表明,在校正肌酐清除率后,年龄作为协变量对这两种药物的表观清除率有额外影响。PBPK模拟结果表明,疾病特异性病理生理变化可以解释年轻老年人中DAB的暴露情况。在老年人群中,17.1%的DAB暴露增加仍无法解释,通过敏感性分析最终获得了25.5%与衰老相关的P-gp功能降低。使用PBPK建模获得的地高辛数据进一步验证了该值。模拟结果表明,高龄且中度至重度肾功能损害的CHF患者在使用DABE和地高辛期间需要提高对暴露风险增加的警惕。
在中国高龄老年人群中,衰老可能是通过降低P-gp介导的外排作用导致DAB和地高辛全身暴露增加的重要危险因素。